A Multicenter, Randomized, Double-masked, Placebo-controlled Phase II Study to Assess the Safety and Efficacy of a Standardized Orally Administered Silymarin Preparation (Legalon) for the Treatment of Patients With Chronic Hepatitis C Who Failed Conventional Antiviral Therapy.

Trial Profile

A Multicenter, Randomized, Double-masked, Placebo-controlled Phase II Study to Assess the Safety and Efficacy of a Standardized Orally Administered Silymarin Preparation (Legalon) for the Treatment of Patients With Chronic Hepatitis C Who Failed Conventional Antiviral Therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2014

At a glance

  • Drugs Silymarin (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms SyNCH
  • Most Recent Events

    • 18 Jul 2012 Results published in JAMA: the Journal of the American Medical Association.
    • 27 May 2012 New trial record
    • 22 May 2012 Substudy results presented at Digestive Disease Week 2012.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top